Cheapest GLP-1 Provider 2026

1. 2026 price tiers (full overview)

GLP-1 access in 2026 splits across five effective price tiers, each with different trade-offs on FDA-status, support quality, and supply continuity:

2. Tier 1: $0-25/month with insurance + savings

The cheapest sustainable path is commercial insurance coverage combined with a manufacturer savings card.

• NovoCare savings card (Wegovy, Ozempic, Saxenda, Rybelsus, Victoza): $0-25/month copay for commercially-insured patients. Annual savings capped ~$3,600.
• LillyCares savings (Zepbound, Mounjaro, Trulicity): Similar $0-25/month copay assistance for commercial insurance.

Excluded: Medicare, Medicaid, federally-funded plans (TRICARE, VA), uninsured patients. These exclusions are due to federal anti-kickback rules that prevent manufacturer subsidies of government-funded prescriptions.

For Medicare patients: Wegovy is now covered under its 2024 cardiovascular indication for eligible Part D patients with established CVD. See our Insurance Coverage 2026 guide for full Medicare + Medicaid landscape.

3. Tier 2: $129-199/month compounded semaglutide

Compounded semaglutide via telehealth is the cheapest documented option in 2026. Major providers and approximate floors:

• Sesame + third-party pharmacy: ~$129/month (DIY route — requires sourcing telehealth visit + pharmacy separately)
• Lemonaid Health: $129/month introductory pricing
• Embody Flat Program: Under $150/month
• Ro: $149/month starting
• Henry Meds: $149-199/month
• Noom: $149/month starting
• GobyMeds: $169-499/month tiered by dose
• Shed: $199-299/month tiered by dose

Important trade-offs:

• NOT FDA-approved as finished product — see our compounded buyer's guide for safety + verification
• Legal basis narrowed after FDA resolved semaglutide shortage February 2025
• 30+ compounding companies received FDA enforcement actions in 2026
• Hims exited compounded GLP-1s in early 2026 — signal that the category is shrinking
• Supply continuity not guaranteed — your $129 program could disappear if compounder loses access

4. Tier 3: $349-499/month LillyDirect Zepbound

Eli Lilly's LillyDirect program sells Zepbound single-dose vials direct-to-consumer at fixed cash prices, regardless of insurance status:

• Zepbound 2.5mg starter vial: $349/month
• Zepbound 5mg: $499/month
• Zepbound 7.5-15mg maintenance vials: $499/month

This is the cheapest FDA-approved tirzepatide path in 2026. Key features:

• FDA-approved finished product (Zepbound, full FDA oversight)
• Direct from manufacturer (no pharmacy markup)
• Cash-pay only — does not bill insurance
• Available nationwide
• Self-injection from vial (vs autoinjector pens) — slightly more dexterity required

For semaglutide-equivalent FDA-approved option, Novo Nordisk launched a similar Wegovy direct program in 2025 but pricing has been higher than LillyDirect (~$499-650/month). Compare both via our Wegovy and Zepbound drug pages.

5. Tier 4: $650/month NovoCare Wegovy (uninsured)

NovoCare offers a savings program for uninsured Wegovy patients that brings monthly cost to approximately $650 — about half of full retail. Eligibility:

• US adults aged 18+
• Uninsured (no commercial coverage, not on Medicare/Medicaid)
• Valid prescription for Wegovy
• Application through Novo Nordisk Patient Assistance enrollment

This is the cheapest FDA-approved semaglutide for the uninsured. The annual cost (~$7,800) is still substantial — if $650/month exceeds your budget, the compounded tier 2 or LillyDirect Zepbound tier 3 (different molecule but same weight-loss outcome category) may be more accessible.

6. Tier 5: Full retail $998-1,349/month

Without insurance or savings programs, list prices are:

• Wegovy: $1,349/month
• Saxenda: $1,349/month
• Mounjaro: $1,086/month
• Zepbound: $1,086/month
• Ozempic: $998/month
• Rybelsus: $998/month
• Trulicity: $987/month

Few patients pay full retail in practice — most have either insurance coverage, savings card eligibility, or use a manufacturer-direct or compounded program. If you're paying retail, you almost certainly have a cheaper option available; start with our Insurance Coverage 2026 guide to identify which tier you qualify for.

7. The 2026 compounding crackdown

Key events shaping the 2026 compounded GLP-1 landscape:

• February 2025: FDA resolves semaglutide shortage. Legal basis for mass-compounding under shortage exemption ends.
• March 2025: Compounding industry groups file litigation challenging FDA resolution; partial injunctions issued in some districts.
• Late 2025: FDA issues warning letters to multiple compounding pharmacies; first round of enforcement actions.
• Early 2026: Hims announces exit from compounded GLP-1 category. Other major telehealth platforms scale back.
• Mid-2026: FDA enforcement against 30+ companies. Compounded GLP-1 market continues shrinking but smaller compounders remain.

Expected through 2026-2027: continued enforcement, possible settlement or legal clarity for traditional 503A compounding, continued telehealth platform consolidation toward FDA-approved options.

8. Interactive cost projection

Project your 12, 24, and 36-month total spend by drug + coverage scenario:

9. Decision tree by your situation

• If you have commercial insurance: First check if your plan covers Wegovy or Zepbound. If yes, add the manufacturer savings card → $0-25/month. This is the cheapest sustainable path.
• If you have Medicare: Check if you qualify for Wegovy CVD coverage (established cardiovascular disease + BMI ≥27). Diabetes-indicated GLP-1s (Ozempic, Mounjaro) typically covered.
• If you have Medicaid: Check state-specific coverage. About 13 states cover GLP-1s for chronic weight management.
• If you're uninsured + want FDA-approved: LillyDirect Zepbound ($349-499/month) is the cheapest. NovoCare Wegovy ($650/month) if you specifically need semaglutide.
• If cost is the primary barrier: Compounded semaglutide ($129-199/month) via verified state-licensed pharmacy. Read our buyer's guide first.
• If you're not sure where you fit: Take our 3-question quiz for a personalized recommendation.

10. Frequently asked questions

What is the cheapest GLP-1 medication in 2026?

Compounded semaglutide via Sesame + third-party pharmacy is the cheapest documented option at approximately $129/month — but it requires sourcing your own telehealth visit and pharmacy. Bundled telehealth programs (Ro, Henry Meds, Embody, Lemonaid) start around $149-199/month for compounded semaglutide. For FDA-approved options, LillyDirect Zepbound single-dose vials at $349/month is the cheapest FDA-approved route in 2026.

Is $129/month for semaglutide too good to be true?

It's real but comes with trade-offs. Compounded semaglutide at this price is NOT FDA-approved as a finished product. The FDA resolved the semaglutide shortage in February 2025, narrowing the legal basis for mass compounding. In 2026, the FDA has taken enforcement actions against 30+ compounding companies. Lower prices reflect lower regulatory oversight, not lower-quality molecule — but quality and legal availability depend on the specific pharmacy.

What's the cheapest FDA-approved GLP-1 in 2026?

LillyDirect Zepbound single-dose vials at $349/month (2.5mg starter) up to $499/month (15mg maintenance) is the cheapest FDA-approved option. This is direct-from-manufacturer cash-pay (not through insurance). For semaglutide specifically, NovoCare savings programs can lower Wegovy to ~$650/month for uninsured patients. With commercial insurance + savings cards, both Wegovy and Zepbound can drop to $0-25/month copay.

Why did Hims exit compounded GLP-1s?

In early 2026, Hims announced it would stop offering compounded GLP-1 medications. The decision followed FDA enforcement actions against compounding manufacturers post-shortage-resolution. Hims continues to offer FDA-approved Wegovy through partner pharmacies. The exit signals broader market shift toward FDA-approved options as the compounding legal landscape narrows.

Can I get GLP-1 free or near-free with insurance?

Yes, if you qualify. Commercial insurance with a manufacturer savings card (NovoCare for Wegovy/Ozempic, LillyCares for Zepbound/Mounjaro) can reduce copay to $0-25/month. Eligibility excludes Medicare, Medicaid, and uninsured patients. Annual savings are typically capped around $3,600. For Medicare beneficiaries, Wegovy is now covered under its 2024 cardiovascular indication for eligible patients.

Is the cheapest option always the best?

No. The "cheapest" question hides three trade-offs: (1) regulatory oversight — compounded products are not FDA-reviewed as finished products; (2) supply continuity — compounded programs may face legal restrictions; (3) provider support quality — bundled telehealth programs offer dose titration support and prescriber access that DIY routes don't. Pick based on your priorities: cost, oversight, support level, and risk tolerance.

• Editorial board reviewed
• CC BY 4.0 data
• FDA-source citations
• Affiliate disclosed

Pricing reflects publicly-stated 2026 cost structures and is subject to change. Compounded products are NOT FDA-approved as finished products. GLP1Zoom is affiliate-disclosed and earns commission from some partner providers; this guide includes providers regardless of partnership status. Always confirm current pricing directly with providers. Full disclaimer.